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Abstract
Aims/hypothesis In addition to weight loss, bariatric sur-
gery for severe obesity dramatically alleviates insulin
resistance. In this study, we investigated whether circulating
concentrations of the high-molecular-weight (HMW) form
of adiponectin are increased following gastric bypass
surgery. The HMW form is implicated as the multimer
responsible for adiponectin’s hepatic insulin-sensitising
actions.
Subjects and methods We studied 19 women who were
undergoing Roux-en-Y gastric bypass surgery. Studies were
conducted prior to, and 1 and 12 months after surgery.
Results One month after surgery, total plasma adiponectin
concentrations were unchanged. Nevertheless, increases in
both HMW (by 40±15%, p=0.006) and the proportion
of adiponectin in the HMW form (from 40±2 to 50±2%,
p<0.0001) were observed. At 12 months, total and HMW
adiponectin concentrations were increased by 58±8% and
118±21%, respectively (both p<0.001). The majority
(80%) of the increase of total adiponectin was due to an
increase of the HMW form. After adjustment for covariates,
increases of HMW and total adiponectin at 12 months were
correlated with the decrease of fat mass (HMW, p=0.0076;
total, p=0.0302). In subjects with improved insulin sensi-
tivity at 12 months after surgery (n=18), the increase of
HMW, but not that of total adiponectin, predicted the
relative decrease of insulin resistance (HMW: p=0.0044;
total: p=0.0775, after adjustment for covariates).
Conclusions/interpretation These data suggest that the
reduction of fat mass following gastric bypass surgery is
an important determinant of the increase of HMW
adiponectin concentrations, which in turn is associated with
and may contribute to the resulting improvement of insulin
sensitivity.
Keywords Adiponectin . Clinical science . Gastric bypass .
Human . Insulin sensitivity .Weight regulation
Abbreviations
FSIVGTT frequently sampled intravenous glucose
tolerance test
HMW high molecular weight
HOMA-
IR
homeostatic model assessment of insulin
resistance
LMW low molecular weight
MMW medium molecular weight
SA ratio of HMW adiponectin to total adiponectin
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Introduction
Bariatric surgery is currently the most effective treatment
for achieving long-term weight reduction in people with
severe obesity [1–3]. In addition to marked weight loss,
bariatric surgery often ameliorates or resolves obesity-
related co-morbidities, particularly insulin resistance and
type 2 diabetes [4, 5]. The mechanisms involved in this
improvement in insulin sensitivity are likely to involve the
immediate reduction in food intake (accompanied by
modulation of intestinal incretin hormones) [6], followed
by the reduction of excess adiposity [7].
Adipose tissue produces a number of hormones, known
as adipokines, that signal changes in adipose mass and
energy status [8]. One of these adipokines, adiponectin, has
insulin-sensitising actions in liver and skeletal muscle and
anti-inflammatory/anti-atherosclerotic effects on vascular
endothelium [9]. The effects of adiponectin leading to
improved insulin sensitivity are mediated in part by its
activation of AMP kinase, which leads to increased fatty
acid oxidation and reduced ectopic triglyceride deposition
in liver and muscle [8, 10]. Plasma adiponectin concen-
trations are reduced in obese humans [11], and decreased
circulating levels are independently associated with an
increased risk of insulin resistance and type 2 diabetes [12].
Adiponectin circulates in three major forms: as trimers
(low molecular weight [LMW]), as hexamers (medium
molecular weight [MMW]) and as larger multimers of 12 to
18 subunits (high molecular weight [HMW]) [13]. The
production and therefore circulating levels of the different
molecular-weight complexes appear to be regulated at the
level of the adipocyte [14, 15]. The three major forms of
adiponectin differentially activate signalling pathways in
target tissues. For example, in cultured myocytes and
isolated skeletal muscle, HMW and MMW, but not LMW
complexes activate nuclear factor-κB, whereas the LMW
form alone activates AMP kinase [16]. In cultured
hepatocytes, however, AMP kinase is only activated by
the larger MMW and HMW complexes [13]. HMW has
been reported to be the only multimeric form of adiponectin
that prevents apoptosis of cultured human endothelial cells
[17]. In addition, HMW, but not MMW adiponectin
effectively lowers blood glucose levels in adiponectin-
deficient mice [14].
The importance of the HMW adiponectin complex in the
regulation of insulin action is further supported by the
observations [14] that the ratio of HMW adiponectin to total
adiponectin (SA) was reduced in human subjects with type 2
diabetes and in db/db mice. Furthermore, following thia-
zolidinedione treatment of patients with type 2 diabetes
(which increases total adiponectin levels), the increase of SA,
but not the increase of total adiponectin was strongly
correlated with improvements of insulin sensitivity and
lowering of hepatic glucose production [14]. Similarly, a
recent study reported that HMW adiponectin concentrations
were better correlated than total adiponectin concentrations
with a number of components of the metabolic syndrome
[18].
Circulating concentrations of total adiponectin (all
forms) have been shown to increase following bariatric
surgery [19–22], and may be predictive of post-operative
insulin sensitivity [19] and improvement of beta cell
function [20]. However, the effect of weight loss surgery
on the distribution of the different molecular weight
adiponectin complexes has not been previously examined.
Accordingly, we determined the amount and distribution of
the HMW, MMW and LMW forms of circulating adipo-
nectin in severely obese subjects undergoing Roux-en-Y
gastric bypass surgery.
Subjects and methods
Protocol
We studied 19 morbidly obese women who were undergo-
ing Roux-en-Y gastric bypass surgery at the University of
California, Davis Medical Center, or at Mercy San Juan
Hospital in Sacramento, California. Prior to, and at 1 month
and 12 months after surgery, fasting blood samples were
collected and body composition was assessed at the
University of California Davis General Clinical Research
Center (Mather Field Department of Veterans Affairs
Medical Center, Rancho Cordova, CA, USA). The Institu-
tional Review Board of the University of California Davis
approved the experimental protocol, and all subjects
provided written informed consent to participate in the
study.
Biochemical and anthropometric measurements
Insulin was measured by radioimmunoassay (Linco, St.
Charles, MO, USA) and glucose was measured with a
glucose analyser (YSI, Yellow Springs, OH, USA).
Homeostatic model assessment of insulin resistance
(HOMA-IR) was calculated as previously described [23].
Non-esterified fatty acid concentrations were measured
using an enzymatic colorimetric assay (Waco Chemicals,
Richmond, VA, USA). Adiponectin multimers were mea-
sured in duplicate by ELISA (ALPCO Diagnostics, Salem,
NH, USA), a method which has recently been validated
against western blot analysis [24]. In addition to measuring
total adiponectin, the ELISA uses two separate protease
treatments to digest either the LMW or the LMW+MMW
adiponectin, enabling HMW+MMW adiponectin and
HMW adiponectin alone to be measured. MMW and
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LMW adiponectin are then calculated by subtraction. In our
laboratory, the inter-assay coefficients of variation for total,
HMW+MMW, and HMW adiponectin were 9.8, 10.8, and
12.9%, respectively. Intra-assay CVs for each of the three
were <6.9, <6.5, and <10%, respectively.
Body composition was determined using air-displace-
ment plethysmography (BodPod Body composition system,
Life Measurements, Concord, CA, USA). Body weight,
height, waist and hip circumference were measured by a
trained nurse using standard methods.
Statistical analysis
All data are presented as mean±SEM. Univariate and
bivariate statistical analyses were performed using GraphPad
Prism v. 4 (San Diego, CA, USA) software. Prior to analysis,
all continuous variables were assessed for normality using the
Kolmogorov–Smirnov test. Correlations between normally
distributed continuous variables were assessed using
Pearson’s correlation. Significant differences between levels
prior to and at 1 and 12 months after surgery were assessed
either by one-way repeated measures ANOVA or its non-
parametric equivalent, the Friedman test. Bonferroni
correction was used for multiple post-test comparisons.
Multivariate analysis was performed using the standard
least squares method (JMP Start Statistics, SAS Institute,
Cary, NC, USA). To assess the relationship between changes
in either HMW or total adiponectin and fat mass, changes in
HMWor total adiponectin were entered into the model as the
response (dependent) variable, and age, initial BMI and the
change in fat mass were entered as predictor (independent)
variables. For the relationship between the relative change in
HOMA-IR and changes in HMW or total adiponectin, the
percent change in HOMA-IR was entered into the model as
the response (dependent variable), and age, change in HMW
or total adiponectin, as well as the change in plasma NEFA
concentrations (which might also influence insulin sensitiv-
ity) were entered as predictor (independent) variables. A
p-value of <0.05 was considered significant.
Results
Prior to surgery
The 19 female patients studied were undergoing Roux-en-Y
gastric bypass surgery and were aged 40.6±1.8 years (mean±
SEM; range 25–50), with a BMI of 45.6±1.6 kg/m2 (range
36.8–64.9). Pre-operatively, three patients had diabetes
mellitus (fasting plasma glucose ≥7.0 mmol/l). Plasma
glucose, insulin, HOMA-IR, NEFA and measures of body
composition prior to surgery and at 1 month and 12 months
after surgery are presented in Table 1. Pre-operative
adiponectin concentrations were low, as would be expected
in morbidly obese subjects (total adiponectin 4.4±0.4 μg/ml
[mean±SEM]; range 2.4–8.4 μg/ml). SA values averaged
40±2% (mean±SEM; range 24–54%) and were comparable
with values previously reported in humans [13, 14]. Prior to
surgery, no significant correlations were observed between
measures of adiponectin (total adiponectin, individual multi-
mers, or SA) and body composition (weight, BMI, fat mass,
lean mass) or fasting insulin, glucose or HOMA-IR.
Results at 1 month
One month after gastric bypass surgery, BMI, body weight,
fat mass and lean body mass were all decreased by 10 to
12% (Table 1). Waist circumference was also significantly
reduced, as were fasting insulin concentrations and HOMA-
IR, while plasma NEFA concentrations were significantly
Table 1 Changes in body composition and measures of insulin resistance in Roux-en-Y gastric bypass patients
Characteristic Pre-operative 1 month 12 months Overall p
(n=19) (n=19) (n=19)
Body weight, kg 126.4±3.6 113.4±3.3*** 85.9±2.8*** <0.0001
BMI, kg/m2 45.6±1.6 41.0±1.5*** 30.8±1.0*** <0.0001
Fat mass, kg 65.5±2.7 58.2±2.5** 32.9±1.8*** <0.0001
Lean mass, kg 60.9±2.0 55.2±1.6*** 53.0±2.5*** <0.0001a
Waist circumference, cm 130±2 119±3* 100±2*** <0.0001
Waist-to-hip ratio 0.95±0.03 0.90±0.02 0.88±0.02** 0.0047
Fasting insulin, pmol/l 201±18 117±11*** 77±6*** <0.0001
Fasting glucose, mmol/l 5.5±0.3 5.1±0.2 4.6±0.1*** <0.0001
NEFA, mmol/l 0.28±0.03 0.37±0.04* 0.20±0.02* <0.0001
HOMA-IR 7.4±1.0 4.0±0.5*** 2.3±0.2*** <0.0001
All data are shown as mean±SEM. Significant differences between pre-operative levels and 1 and 12 months post-surgery were assessed by one-way
repeated measures ANOVA (or its non-parametric equivalent, Friedman testa ). *p<0.05, **p<0.01, ***p<0.001 relative to pre-operative levels
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increased (all p<0.05). Fasting glucose concentrations were
normalised in the three subjects with overt diabetes prior to
surgery. While total plasma adiponectin concentrations
were unchanged 1 month after surgery (from 4.4±0.4 to
4.5±0.3 μg/ml [mean±SEM]; p=0.78), a redistribution of
adiponectin oligomers, away from the MMW and LMW
forms and towards the HMW form, was already apparent
(Fig. 1a). The absolute amount of HMW adiponectin was
increased by 40±15% relative to pre-operative levels (from
1.8±0.2 μg/ml to 2.3±0.2 μg/ml, p=0.006). Accordingly,
SA increased from 40±2% pre-operatively to 50±2%
(mean±SEM; range 39–64%) at 1 month (p<0.001 vs
pre-operative), and the proportion of adiponectin in the
MMW form was reduced (Fig. 1b).
Results at 12 months
By 12 months, subjects had lost 32±2% of their initial
weight and 50±3% of fat mass (p<0.001 relative to pre-
operative levels for both). Total adiponectin concentration
was increased relative to before surgery, (from 4.4±0.4 to
6.9±0.6 μg/ml, Δ=+2.5±0.3 μg/ml; p<0.001), and most
of the increase (80% or 2.0 μg/ml of the total increase of
2.5 μg/ml) was due to an increase of the HMW form
(Fig. 1a). The concentration of MMW adiponectin also
increased, from 1.0±0.1 μg/ml before surgery to 1.6±
0.2 μg/ml at 12 months (Δ=0.6±0.1 μg/ml, p<0.001),
whereas LMW adiponectin concentrations were unchanged
(1.5±0.1 μg/ml pre-operatively and at 12 months).
Relationships between adiponectin multimers
and adiposity/body composition
The change in HMW adiponectin concentrations over the
12 months was related to changes in several measures of
adiposity/body composition. At 12 months following surgery,
the change in HMW adiponectin was inversely proportional
to the changes in body weight (r=− 0.47, p=0.022), BMI
(r=−0.54, p=0.0087), waist circumference (r=−0.42, p=0.041)
and fat mass (r=−0.49, p=0.017). In contrast, the change in
total adiponectin concentrations was not as well correlated
with changes in body weight, BMI, waist circumference
and fat mass over the same period (body weight, r=−0.37,
p=0.060; BMI, r=−0.41, p=0.038; waist circumference,
r=−0.13, p=0.31; fat mass, r=−0.38, p=0.054).
The relationship between the change in HMWadiponectin
and the change in fat mass over the 12-month period remained
highly significant in a multivariate analysis (p=0.0076 after
adjustment for age and initial BMI; Table 2). This model
(Model 1) accounted for 49% of the variation in HMW
adiponectin. Accordingly, the change in total adiponectin
over this period (most of which resulted from an increase of
the HMW form) was also significantly associated with the
changes in fat mass, albeit less significantly (p=0.030, when
adjusted for the same covariates). Analysis of the same
variables at 1 month revealed no relationship between
changes in total or HMW adiponectin and the changes in
fat mass (data not shown). In contrast, the changes in MMW,
LMW and SA were not correlated with the changes in fat
mass over the 12 months post-surgery.
Fig. 1 Changes in the absolute amounts (a) and the proportion (b) of
the three adiponectin multimers from pre-operative levels (Pre) to 1 and
12 months (1, 2) after Roux-en-Y gastric bypass surgery. Data are
presented as means±SEM (n=19). Total adiponectin levels were
increased at 12 months, and the absolute amount of high-molecular-
weight (HMW) adiponectin (white bars) was increased at 1 and
12 months (from 1.8±0.2 μg/ml prior to surgery to 2.3±0.2 μg/ml at
1 month and 3.8±0.5 μg/ml at 12 months). The absolute amount of
medium-molecular-weight (MMW) adiponectin (grey bars) was in-
creased at 12 months (1.0±0.1 μg/ml vs 1.6±0.1 μg/ml), while the
amount of low-molecular-weight (LMW) adiponectin (black bars) did
not change significantly during the 12 months. *p<0.05, ***p<0.001
relative to pre-operative levels
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Adiponectin multimers and insulin resistance
We also examined the relationship between the changes in
adiponectin multimers and HOMA-IR. After excluding one
subject, who displayed no significant improvement (<15%
decrease) in HOMA-IR (a ‘non-responder’ to use Pajvani et
al.’s classification [14]), subjects with the largest increases
in HMW adiponectin at 12 months post-surgery exhibited
the greatest relative improvements in HOMA-IR over the
same period (r=−0.43, p=0.036) (Fig. 2a). The relative
decrease in HOMA-IR over the 12-month period was not
significantly correlated with the changes in MMW+LMW
(Fig. 2b), LMW (r=0.15, p=0.28), MMW (r=−0.07, p=0.38),
or total adiponectin concentrations (r=−0.33, p=0.092)
or SA (r=−0.18, p=0.23).
The relationship between the change in HMW adipo-
nectin and the percent change in HOMA-IR was more
pronounced after adjustment for age and the change in
plasma NEFA concentrations (p=0.0044, Model 3, Table 2).
When adjusted for the same covariates, the change in total
adiponectin concentrations was not related to the percent-
age change in HOMA-IR (p=0.0775, Model 4). No
significant correlations were observed between changes in
total adiponectin, adiponectin multimers or SA and changes
in HOMA-IR at 1 month after surgery.
Discussion
In the present study, we measured circulating levels of
adiponectin oligomers before and after Roux-en-Y gastric
Fig. 2 The change in high-molecular-weight (HMW) (a), but not in
low-molecular-weight (LMW)+medium-molecular-weight (MMW)
adiponectin (b) is correlated with the relative improvement of
HOMA-IR following gastric bypass surgery. The change in HMW
adiponectin in the 12 months post-surgery was associated with the
relative improvement in HOMA-IR over the same period (r=−0.43,
p=0.036 in univariate analysis; p=0.0044 after adjustment for
covariates). There was no correlation between the change in LMW+
MMW adiponectin concentrations and the relative improvement in
HOMA-IR (r=0.06, p=0.41)
Table 2 Multivariate analysis of the relationship between changes in adiponectin and HMW adiponectin and fat mass in gastric bypass subjects
over 12 months
Model n Dependent variable Independent variables β SE p Model R2 (adj)
1 19 Δ HMW adiponectin Δ fat mass (kg) −0.0839 0.0272 0.0076 0.49
(μg/ml) Age (years) 0.0963 0.0283 0.0039
Pre-operative BMI (kg/m2) −0.0123 0.0386 0.75
2 19 Adiponectin Δ fat mass (kg) −0.0757 0.0316 0.0302 0.40
(μg/ml) Age (years) 0.1062 0.0329 0.0057
Pre-operative BMI (kg/m2) −0.0144 0.0449 0.75
3 18 %Δ HOMA-IR Δ HMW adiponectin (μg/ml) −9.4560 2.7892 0.0044 0.49
Age (years) 0.6108 0.3518 0.10
Δ NEFA (mmol/l) −83.6151 23.7474 0.0034
4 18 %Δ HOMA-IR Δ Adiponectin (μg/ml) −5.2826 2.7726 0.0775 0.26
Age (years) 0.4230 0.4232 0.33
Δ NEFA (mmol/l) −69.4413 27.7742 0.026
Analysis was performed using the standard least squares method. Abbreviations: β, coefficient; SE, standard error; R2 , proportion of the variance
accounted for by the model.
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bypass surgery in a group of 19 morbidly obese women.
Both the absolute amount of HMW adiponectin and the
proportion of adiponectin in the HMW form were increased
significantly at 1 month after surgery, by which time
subjects had lost ∼10% of their weight. However, total
plasma adiponectin concentrations were not significantly
increased at this time, as the concentrations of MMW and
LMW adiponectin were reduced. At 12 months post-
surgery, both total and HMW adiponectin were increased,
on average, by 58±8% and 118±21%, respectively (both
p<0.001), with the percentage of HMW adiponectin remain-
ing increased (at 52±2% of total). The change in HMW
adiponectin in these subjects was more closely related to the
change in fat mass over the 12-month follow-up period than
was the change in total plasma adiponectin concentrations,
this finding being independent of age and BMI prior to
surgery. In the 18 subjects with improved insulin resistance as
a result of surgery, the change in HMW adiponectin, but not
the change in total adiponectin or any of the other forms
predicted the relative improvement in HOMA-IR.
Weight loss after gastric bypass surgery has been
previously demonstrated to increase circulating total adipo-
nectin concentrations [19–22], probably reflecting reduced
adiposity, and a reduction of adipocyte size. In support of
this hypothesis, we observed a strong inverse relationship
(r=−0.78, p<0.002) between adipocyte volume and adipo-
nectin secretion from isolated rat adipocytes in vitro
(unpublished observation, P. J. Havel, K. L. Stanhope).
While the impact of gastric bypass on adiponectin multi-
mers has not been previously investigated, a few studies to
date have examined the effects of diet-induced weight loss,
with conflicting results [17, 25, 26]. The discrepancies
between some of the results of other studies and the present
study may reflect either the substantially lesser degree of
weight loss induced by lifestyle versus surgical interven-
tions (6–9%), or the greater severity of obesity in the
subjects in the present study. Severe caloric restriction may
also play a role, as one study reported increases of total and
HMW adiponectin in moderately obese subjects maintained
on a diet of 800 kcal/day [17].
Insulin resistance, as assessed by marked decreases in
fasting insulin concentrations and HOMA-IR, was dramat-
ically improved at both 1 and 12 months after surgery. In
this study, we found that the relative change in HOMA-IR
at 12 months was more closely related to the increase in
HMW than to those in MMW, LMW, or total adiponectin
concentrations in patients in whom insulin sensitivity was
improved. This observation remained significant in multi-
variate analysis, and is consistent with what has been
reported in insulin-resistant and diabetic subjects treated
with thiazolidinediones, in that the increase in total
adiponectin levels is primarily due to an increase of the
HMW form [14, 26], and the increase in the proportion of
HMW adiponectin is predictive of improved insulin
resistance and hepatic glucose production [14].
However, in contrast to Pajvani et al. [14], we found that
the absolute increase in HMW adiponectin, and not the
proportion of adiponectin in the HMW form (SA) was related
to increased insulin sensitivity. In this regard, our findings
are more in agreement with those of Lara-Castro et al. [18],
who observed that the absolute amount of HMWadiponectin
was better related to differences in insulin sensitivity among
humans than was SA. While it is unclear which factors could
explain this discrepancy, one possible explanation is the
different measurements used to assess insulin sensitivity.
Pajvani et al. [14] found that the relative change in SA was
better than the absolute amount of HMW adiponectin at
predicting relative (%) changes in insulin sensitivity (derived
from Minimal Model analysis of frequently sampled
intravenous glucose tolerance test [FSIVGTT] data) and
hepatic glucose output (derived from a hyperinsulinaemic–
euglycaemic clamp). This result was consistent with their
data in animals that HMW, but not hexameric (MMW)
adiponectin dose-dependently suppressed glucose levels in
adiponectin-deficient mice; and that these mice display
hepatic, rather than peripheral insulin resistance [27]. In
contrast, Lara-Castro et al. [18] observed that the maximally
stimulated glucose disposal rate during hyperinsulinaemic
clamps correlated better with the absolute amount of HMW
adiponectin than with SA. Regarding insulin sensitivity,
measurements from these two studies are not directly
comparable with each other (or with the present study), as
the maximal level of insulin-stimulated glucose disposal
used in one study [18] would have completely suppressed
(and precluded the measurement of) hepatic glucose output.
In the present study, the use of HOMA-IR as a measure of
insulin sensitivity, while convenient, does not assess dynam-
ic changes in insulin sensitivity and glucose disposal. In non-
diabetic subjects, HOMA-IR is largely a reflection of fasting
insulin levels [28].
There were a few limitations to the present study. The
major limitation is the small number of subjects and the fact
that all subjects were women. Women typically have higher
levels of total and HMW adiponectin [14], which may be
due to suppression of the HMW form by testosterone [15].
A second limitation is our use of HOMA-IR, which is not
the optimal method for determining insulin sensitivity/
resistance, particularly in small groups of subjects. How-
ever, it was not possible to perform euglycaemic clamps or
FSIVGTTs/Minimal Model analysis on the subjects in the
present study.
In summary, we have demonstrated for the first time that
circulating concentrations of HMW multimeric adiponectin
are increased as early as 1 month after gastric bypass
surgery. Twelve months after surgery, the increase in HMW
adiponectin was related to the loss of body fat, while the
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relative improvement in insulin sensitivity after surgery-
induced weight loss was related to the increase in HMW
adiponectin concentrations. These relationships were not
observed at 1 month after surgery, and were considerably
less significant when total adiponectin concentrations were
examined. Thus, our results are consistent with the
emerging view that altered adipokine secretion may
contribute to the long-term alleviation of insulin resistance
and diabetes following this increasingly common surgical
procedure. Further studies are needed to determine whether
increased production of HMW multimeric adiponectin by
adipose tissue after gastric bypass surgery is a response to
the marked degree of caloric restriction and/or decreased
adipocyte size.
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